Background: Breast cancer is the leading cancer among Indian women. Sentinel lymph node biopsy (SLNB) is the preferred method for axillary staging in early breast cancer with clinically negative nodes (cN0), reducing the need for axillary lymph node dissection (ALND). The role of SLNB and its implications post-neoadjuvant chemotherapy is unclear. Objectives: To evaluate SLNB in post-neoadjuvant chemotherapy breast cancer patients, assess axillary metastases, residual disease, and cancer staging after chemotherapy. Methods: This study (July 2022 - July 2024) assesses SLNB in 30 breast cancer patients post neoadjuvant chemotherapy and the correlation with ALND, along with the post NAC cancer status Results: Post Neoadjuvant-chemotherapy, 26.7% of patients were down staged to T0, with significant improvements in nodal staging. The SLN identification rate was 90%, with SLNB accuracy at 83% and an 18.4% false-negative rate. Conclusions: NACT is an effective way of downstaging LABC. SLNB using methylene blue dye is cost-effective, reliable, and accurate for lymph node mapping in post-NACT breast cancer patients.